Everything you need to know about our Fusion-detect™ blood-based liver cancer screening test.
The MoleculeDx test screens specifically for hepatocellular carcinoma (HCC) — the most common form of primary liver cancer, accounting for 75–85% of all liver cancer cases in the US.
We analyze circulating tumor DNA (ctDNA) in your blood for HCC-specific fusion gene signatures. These molecular markers appear in the bloodstream at very early tumor stages — often 12–18 months before imaging can detect a tumor.
| Metric | Fusion-detect™ (MoleculeDx) | Standard AFP Test | Ultrasound Alone |
|---|---|---|---|
| Overall Accuracy | 96.7% | ~52% | ~63% |
| Sensitivity (Early Stage) | 94.2% | ~41% | ~47% |
| Specificity | 98.1% | ~87% | ~91% |
| Detects Stage I HCC | ✓ Yes | Often No | Often No |
| Invasive Procedure | None | None | Hospital Req. |
| At-Home Collection | ✓ Yes | No | No |
| Result Turnaround | 24 Hours | 24–48 hrs | 1–2 weeks |
No hidden fees. No surprise bills. And our team will verify your insurance coverage for free before you schedule.
Single liver cancer screening test with full digital report.
Twice-yearly testing with priority service and dedicated support.
© 2024 MoleculeDx Inc. All rights reserved.
This test is not a substitute for medical diagnosis. Consult your physician with all results.
